Search results
NIH Study Confirms: Humans Unlikely To Catch Deer Prion Disease
SciTechDaily· 5 hours agoResearch on cerebral organoids provides strong evidence for a significant species barrier. A recent...
High Confidence AD Drug Donanemab Will Get FDA Panel Nod
Medscape· 3 days agoThe FDA delayed its decision on whether to approve the antiamyloid agent back in March, opting...
Proteomic profiling reveals diagnostic signatures and pathogenic insights in multisystem...
Nature· 2 days agoProteomic profiling reveals diagnostic signatures and pathogenic insights in multisystem inflammatory syndrome in children.
Annexon’s neurological disease drug meets main goal of late-stage study
WSAU Wausau· 3 days ago(Reuters) -Annexon said on Tuesday its experimental drug to treat a rare neurological disease met the main goal of a late-stage trial, sending its shares up more than 31% ...
A Promising New Blood Test for Colorectal Cancer Is in the Works—Here’s What You Should Know
Self via Yahoo News· 7 days agoThis means the Shield test isn’t an option for high-risk people of any age, including those with a...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 50 minutes agoHONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in
Scientists identify gene linked to developmental disorders - UPI.com
UPI· 3 days agoMutations in a single newly identified gene are responsible for developmental disorders affecting...
Childhood sedentariness may cause premature liver damage in young adulthood
Medical Xpress· 5 days agoChildren who are sedentary for more than six waking hours a day have a significantly increased risk...
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with...
Benzinga· 2 days agoNew data from the ELATIVE® Phase III trial show 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeksData from the itch
Allergy-immunology specialists Dang and Patel named 2024 Castle Connolly Top Doctors
Digital Journal· 3 days ago24-7 Press ReleaseAndrew T. Dang, MD, and Gital K. Patel, MD, have been recognized as 2024 Castle Connolly Top Doctors — the first year for both to receive the prestigious ...
